Warning: This security is no longer trading.
Sobi Successfully Completes Acquisition of Dova Pharmaceuticals
Dova Pharmaceuticals, Inc. (DOVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
DOVA Stock Summary
- With a price/sales ratio of 60.82, NA has a higher such ratio than 97.48% of stocks in our set.
- As for revenue growth, note that DOVA's revenue has grown 189.88% over the past 12 months; that beats the revenue growth of 96.96% of US companies in our set.
- In terms of volatility of its share price, DOVA is more volatile than 94.25% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to NA, a group of peers worth examining would be SNES, DERM, IGC, NEPT, and ECOR.
DOVA Stock Price Chart Interactive Chart >
DOVA Price/Volume Stats
| Current price | $28.04 | 52-week high | $28.54 |
| Prev. close | $28.00 | 52-week low | $5.62 |
| Day low | $28.00 | Volume | 1,488,000 |
| Day high | $28.19 | Avg. volume | 357,062 |
| 50-day MA | $23.75 | Dividend yield | N/A |
| 200-day MA | $14.16 | Market Cap | 807.61M |
Dova Pharmaceuticals, Inc. (DOVA) Company Bio
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.
DOVA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 30.00% |
| 5-year | N/A |
| YTD | N/A |
| 2020 | N/A |
| 2019 | 0.00% |
| 2018 | -73.68% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...